BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Business

  VANC Pharmaceuticals Executes Share Purchase Agreement to Acquire HealthTab

  HealthTab is a lab-accurate, point-of-care testing platform designed to support the expanding role of pharmacists while offering new potential sources of revenue and growth for pharmacy owners.

  December 4, 2017

   · 

  6 min read
• Business

  CymaBay Therapeutics Strengthens Management Team With Appointment of Paul Quinlan as General Counsel

  As CymaBay’s chief legal officer, he will be responsible for all legal affairs, including providing legal advice to CymaBay’s Board of Directors and senior management.

  December 4, 2017

   · 

  2 min read
• Business

  Oncolix Expands Board of Directors With New Appointment

  OTC-QB requirements are fulfilled with two independent board members appointed.

  December 4, 2017

   · 

  3 min read
• Atox Bio Closes $30M Investment

  The round was led by Arix Bioscience with participation from Adams Street Partners, Asahi Kasei and additional undisclosed investors.

  December 4, 2017

   · 

  3 min read
• Business

  Summit Therapeutics: Notice of Third Quarter Results

  The company will announce its financial results for the third quarter and nine months ended 31 October 2017 on 6 December 2017.

  December 4, 2017

   · 

  1 min read
• Drug Development

  BeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China

  This recognition is in conjunction with China’s 13th “five-year plan” in which the country continues to cultivate major products, solve vital problems and implement projects that achieve qualitative change in the world.

  December 4, 2017

   · 

  4 min read
• Business

  Alligator Bioscience Expands Management Team

  Dr Russell will be responsible for leading Alligator’s clinical team in progressing the company’s immuno-oncology projects towards proof of concept in cancer patients.

  December 4, 2017

   · 

  2 min read
• Business

  Alligator Bioscience Expands Management Team

  Dr Russell will be responsible for leading Alligator’s clinical team in progressing the company’s immuno-oncology projects towards proof of concept in cancer patients.

  December 4, 2017

   · 

  2 min read
• FDA

  Merck’s Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting MS in Canada

  MAVENCLAD is the first and only oral short-course treatment to provide efficacy across key measures of disease activity in patients with RRMS.

  December 4, 2017

   · 

  5 min read
• Resverlogix Closes Previously Announced $87M Private Placement With Shenzhen Hepalink

  Each full warrant is exercisable at a price of $1.64 per share for a period of four years from the closing of the offering.

  December 4, 2017

   · 

  3 min read